Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

2.540 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abeona Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Abeona Therapeutics (ABEO) Q3 2026 Earnings Call Transcript ↗
Management lays out manufacturing targets and a new pipeline asset's path to Phase III. 
Via The Motley Fool
Topics Earnings
US Session Top Movers: FISN, XHLD, TLS Lead Gainers; ZURA, SOC, PLCE Lead Losers ↗
Via Chartmill
Top Movers Today: MF Gains 89.56%, ZURA Falls 72.98% ↗
Via Chartmill
US Gap-Up and Gap-Down Movers for the Nov. 9, 2026 Session ↗
Via Chartmill
News headline image
What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call ↗
Abeona Therapeutics (NASDAQ:ABEO) reported higher ZEVASKYN revenue for the third quarter of 2026 and announced the acquisition of a late-stage drug candidate for eosinophilic esophagitis, as it seeks... 
Via MarketBeat
Topics Earnings
News headline image
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright ↗
Abeona Therapeutics (NASDAQ:ABEO) highlighted the early commercial progress of ZEVASKYN, its autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB),... 
Via MarketBeat
News headline image
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum ↗
Abeona Therapeutics (NASDAQ:ABEO) executives outlined the early commercial rollout of ZEVASKYN, an autologous cell sheet-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), during... 
Via MarketBeat
News headline image
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q2 2026 Earnings Call Transcript ↗
ZEVASKYN revenue surged 31% to $11.4 million as treatment network expanded. 
Via The Motley Fool
Topics Earnings
News headline image
Abeona Therapeutics Q2 2026 Earnings Call Transcript ↗
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For... 
Via Benzinga
Topics Earnings
News headline image
Abeona Therapeutics Q2 Earnings Call Highlights ↗
Abeona Therapeutics (NASDAQ:ABEO) reported second-quarter revenue growth from its ZEVASKYN cell therapy launch while outlining operational challenges involving patient scheduling and manufacturing that... 
Via MarketBeat
Topics Earnings
News headline image
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption 
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
From Abeona Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.